Bruker (NASDAQ:BRKR) Price Target Cut to $75.00 by Analysts at Wells Fargo & Company

Bruker (NASDAQ:BRKR) had its target price cut by Wells Fargo & Company from $78.00 to $75.00 in a report released on Wednesday,Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

Other equities analysts also recently issued reports about the company. TD Cowen reduced their price objective on Bruker from $74.00 to $72.00 and set a “hold” rating for the company in a research report on Wednesday, August 7th. Citigroup cut their target price on Bruker from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Wednesday, July 10th. Wolfe Research downgraded Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. Barclays cut their target price on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, The Goldman Sachs Group cut their target price on Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a research report on Tuesday, July 9th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Bruker currently has an average rating of “Moderate Buy” and an average price target of $79.36.

Bruker Stock Down 4.6 %

Bruker stock traded down $2.76 during midday trading on Wednesday, hitting $57.73. The stock had a trading volume of 1,077,386 shares, compared to its average volume of 1,072,928. The company has a current ratio of 1.65, a quick ratio of 0.75 and a debt-to-equity ratio of 1.18. The stock has a market cap of $8.74 billion, a P/E ratio of 23.95, a P/E/G ratio of 2.32 and a beta of 1.20. Bruker has a 12 month low of $54.55 and a 12 month high of $94.86. The business has a fifty day moving average price of $63.64 and a 200 day moving average price of $66.32.

Bruker (NASDAQ:BRKR) last issued its earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a net margin of 11.29% and a return on equity of 24.92%. The company had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. During the same quarter in the previous year, the firm earned $0.74 earnings per share. The business’s revenue was up 16.4% on a year-over-year basis. Research analysts predict that Bruker will post 2.61 EPS for the current year.

Institutional Trading of Bruker

Several large investors have recently added to or reduced their stakes in BRKR. First Horizon Advisors Inc. raised its stake in Bruker by 120.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 218 shares during the period. Covestor Ltd grew its holdings in shares of Bruker by 139.1% during the 1st quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 210 shares in the last quarter. UMB Bank n.a. grew its holdings in shares of Bruker by 115.3% during the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 354 shares in the last quarter. Gordian Capital Singapore Pte Ltd purchased a new position in shares of Bruker during the 2nd quarter valued at $52,000. Finally, GAMMA Investing LLC grew its holdings in shares of Bruker by 81.0% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock valued at $60,000 after acquiring an additional 388 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.